Study to Evaluate Multiple Doses in Patients With Nasal Polyposis

AK001 is a monoclonal antibody which may be useful in the treatment of patients with moderate
to severe nasal polyposis

Inclusion Criteria:

- TPS of ≥5 for both nostrils with presence on endoscopy of nasal polyps of grade ≥2 in
each nostril according to the polyp grading scale

- History of sinusitis symptoms

- SNOT-22 ≥30

- No clinically significant Screening 12-lead ECG, vital sign, hematology, chemistry, or
urinalysis findings

Exclusion Criteria:

- Use of systemic corticosteroids within 6 weeks of screening

- Chronic use of antibiotic therapy within 3 months prior to Screening

- Nasal surgery (including polypectomy) within 6 months prior to Screening

- Use of investigational drugs or participation in another clinical trial within 30 days
prior to Screening or 5 half‑lives, whichever is longer